Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
KIT NORTON

Edwards Lifesciences Sinks Despite An Earnings Beat, Outlook Increase

Edwards Lifesciences reported slightly better-than-expected second-quarter financials late Wednesday, as sales from its technology to replace faulty heart valves without resorting to open-heart surgery increased 9%. The medtech company also adjusted its full-year profit and revenue outlook. However, EW stock tumbled on earnings.

The California-based company said earnings grew 5% to 66 cents per share while sales increased 11% to $1.53 billion in the second quarter. In constant currency, sales grew 12%. Analysts expected earnings to grow 3% to 65 cents per share with sales totaling $1.5 billion, up 9% vs. the year-earlier quarter.

"We anticipate a year of value creation as we pursue important therapies that will benefit many more patients," Chief Executive Bernard Zovighian said in a written statement Wednesday.

Edward Lifesciences stock plunged 9.8% to close at 82.67 Thursday during market trade. Ahead of earnings on Wednesday, EW edged down a fraction to 91.63.

Before Thursday trade, Edwards Lifesciences stock gained more than 22% in 2023. EW has been trading above its 50-day moving average since June 13. However, Edwards Lifesciences stock's relative strength rating is trending lower.

EW Stock: Earnings Outlook Hiked

Sales of Edwards' key product, its transcatheter aortic heart-valve replacements, or TAVR, totaled $992 million during the quarter, up 9% vs. the year-earlier period. TAVR is a method of replacing a diseased heart valve without resorting to open-heart surgery. Wall Street predicted TAVR sales jumping 9% to $991 million.

Meanwhile, Edwards reported surgical sales jumping 12% to $256 million. Edwards also reported $48 million in sales from its transcatheter mitral and tricuspid therapies. These products treat other valve problems in the heart and don't require surgery.

Edwards expects full-year 2023 sales from $5.9 billion to $6.1 billion, up from the previous estimate of $5.6 billion to $6.0 billion. The company also lifted its 2023 earnings outlook to $2.50 to $2.60 per share, compared with its previous forecast of $2.48 to $2.60.

Edwards also forecast full-year TAVR sales of $3.85 billion to $4.0 billion, with sales growth between 10% and 13% on a constant currency basis, up from 10% to 12%.

EW stock has a Composite Rating of 84 out of 99, with a 54 Relative Strength Rating. Edwards also has an EPS Rating of 90 out of 99.

Please follow Kit Norton on Twitter @KitNorton for more coverage.

YOU MAY ALSO LIKE:

Get An Edge In The Stock Market With IBD Digital

Labor Unions Keep The Heat On Starbucks And Amazon

Tesla Signals IRA Tax Credit Reduction For Model 3

Futures Fall As Fed Decision Looms; Microsoft Slumps On AI Comments

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.